Patient P-01449
Synthetic patientNBL-101 · Day 117 · 45–54 · F · baseline S11Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
8%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S11
- Day 19 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 19.
Primary contributors, last 14 days
- GI instability-14
- Inflammatory activity-7
- Nutritional resilience+3
- Treatment adherence-3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion8.9/100
stable · -0.7 vs previous 14 d
Toxicity
Blood10.5/100
improving · -10.6 vs previous 14 d
Sleep quality
Wearable68.6/100
stable · +1.2 vs previous 14 d
Energy level
Daily log6.5/10
improving · +0.4 vs previous 14 d
Stress level
Daily log2.4/10
improving · -0.6 vs previous 14 d
Steps
Wearable7,192
improving · +370 vs previous 14 d
Adherence
Companion84 %
stable · -3.1 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 78 from the failing basin, 52 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Daily walks resumedperturbation · steering +3.3
Main detractors to watch
- FUT2 non-secretorhidden · steering -10.6
- Bacteroides fragilis elevatedhidden · steering -7.4
- Histamine loadperturbation · steering -5.3
- Dietary driftperturbation · steering -2.6
- Histamine loaddetractor · GI +3.2 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+3.2detractor · 95%
- Spicy / capsaicin-1.3no signal · 37%
- Insoluble fibre-1.1no signal · 24%
- Dietary fat load+1no signal · 25%
- Alcohol-0.6no signal · 17%
- Simple carbohydrates-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Intermediate metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.2 · butyrate capacity 70/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 52 ms
- Sleep
- 7.3 h
- Steps
- 6,572
- Resting HR
- 65 bpm
Daily log: GI score 9, nutritional resilience 70, adherence 84.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.